Companies
Incyte
BiotechnologyWilmington, DelawareINCY2,844 employees
More about Incyte
Biopharmaceutical company that develops and sells medicines for blood cancers, other cancers and inflammatory skin conditions
Revenue
$5.14B
Fiscal 2025, up 21%
Employees
2,844
As of December 2025
Stock
INCY
Nasdaq
Headquarters
Wilmington, Delaware
CEO
Bill Meury
Since June 2025
BrandsJakafi, Opzelura
Current strategyGrowing Jakafi and Opzelura while moving pipeline assets into late-stage development, with 14 pivotal trials expected to be underway by the end of 2026
CompetitorsExelixis, BeiGene, Biogen
Related companiesNovartisVertex PharmaceuticalsRegeneron Pharmaceuticals
Checked October 11, 2026 · Sources: businesswire.com, sec.gov, businesswire.com (2)
No source-backed updates for Incyte yet. They appear here when a public report or filing covers the company.
No one has posted about Incyte yet. Be the first to post ›
Follow Incyte in a feed reader, no account needed: RSS feed